Phase A — Understand the business
Lens 1 · Company Overview
Plain-terms model. Telesis Bio sells "DNA printers" — the BioXp family of automated benchtop instruments that take a digital sequence and physically synthesise genes, gene fragments, clonal DNA, libraries, and (latterly) mRNA overnight, hands-free, on a lab bench, plus the consumable kits/reagents that run on them, plus a services/CRO tail (custom DNA, contract synthesis). The razor-and-blade pitch: place a BioXp (the instrument), then sell recurring kits. The newer bet is the Gibson SOLA™ enzymatic DNA synthesis (EDS) platform — overnight DNA and mRNA on standard liquid-handling robots, no harsh chemicals, sold as a way for pharma to in-source its nucleic-acid supply chain and own the data for AI drug discovery.
Heritage (matters for the moat read). Lineage runs: Synthetic Genomics (J. Craig Venter's company) → carved out as SGI-DNA (2019) → rebranded Codex DNA (2020) → IPO June 2021 as DNAY → renamed Telesis Bio (Nov 2022, ticker TBIO). Founded by Dan Gibson (inventor of Gibson Assembly®, the standard isothermal DNA-assembly method, and CTO) and Todd Nelson (founder-CEO until Apr 2024). The science pedigree is genuinely top-tier — this is not a vaporware shop.
Customers / suppliers / competitors. Customers: pharma/biotech R&D labs and academic cores — as of Dec 31 2022, ~190 unique customers incl. ~105 biopharma companies, ~200 BioXp systems placed globally. Suppliers: enzymes, reagents, electronics/robotics contract manufacturers (NOVO Engineering co-designed the workstation). Competitors: Twist Bioscience (the scaled gorilla), DNA Script (SYNTAX benchtop TdT printer — the most direct head-to-head), Ansa Biotechnologies (long clonal DNA, now IDT-partnered), Molecular Assemblies (shuttered 2024), plus IDT/Genscript/Thermo on the make-it-for-you side. Contract structure: instrument sale + consumable reorders + service contracts — no take-or-pay, no durable lock-in; revenue is lumpy, instrument-led, and (the fatal flaw) never reached recurring-consumable escape velocity.
Lens 2 · Supply Chain
Upstream → company → end customer, named:
- Upstream inputs: modified nucleotides / enzymes (incl. proprietary Gibson SOLA enzyme chemistry and the Gibson Assembly enzyme mix), oligos, reagents; instrument hardware (pipetting/thermal-cycling robotics, optics) built with contract engineering partners (NOVO Engineering co-developed the DNA-printer workstation). Chokepoint: a tiny synbio-tools maker has little supplier bargaining power and carries inventory risk on specialised reagents — visible in the gross-margin blow-up (below).
- The company: assembles/QCs BioXp instruments and packages sequence-specific kits (the recurring SKU); runs (ran) a custom-DNA/CRO service line; the now-divested EtonBio / Eton Bioscience subsidiary was a custom-oligo/antibody-services arm.
- Downstream / end customers: pharma + academic labs (named integrators/users in PR over the years include ImmunoPrecise Antibodies, which integrated the SGI-DNA benchtop DNA printer for antibody discovery). The Gibson-SOLA pivot is explicitly a play to become the upstream supplier inside pharma's own four walls — a Regeneron license (2025) is the marquee downstream-as-partner data point.
- Single-source dependency the OTHER way: the company is now single-sourced on its own balance sheet — Novalis + Northpond are the only capital keeping the chain running. That is the binding chokepoint, not a reagent.
Lens 3 · Competitive Advantages (moats)
What's real: (1) IP + brand heritage — Gibson Assembly is a genuinely canonical method; the Venter/Synthetic Genomics lineage is the most credible provenance in the field; Gibson SOLA enzymatic chemistry is differentiated on paper (overnight, runs on standard liquid handlers, no specialised printer required). (2) First-mover "DNA printer" — BioXp was "the world's first commercially available end-to-end automated benchtop synthetic-biology workstation". (3) A modest installed base (~200 instruments) that should throw off consumable annuities.
Why the moat didn't hold (the load-bearing finding): none of it produced durable switching costs or pricing power. (a) The consumable attach never scaled — instrument-led revenue stayed lumpy and capped at ~$27M; the razor sold, the blades didn't recur fast enough. (b) DNA Script offers the same "benchtop synthesiser" value prop with TdT enzymatic chemistry and more commercial momentum; Twist out-scaled everyone on column/chip synthesis economics; Ansa (with IDT's manufacturing behind it) is pushing read-length leadership (600 bp → targeting 5,000 bp). (c) Bargaining power negative on both sides — couldn't dictate terms to reagent suppliers, couldn't lock in customers who can buy DNA as a service from a dozen vendors. Net: a science moat without a business moat. The market is fragmented (no firm >20% share) precisely because the value prop is substitutable.
Lens 4 · Segments
No segment CSV exists ; reconstructed from PR :
- Revenue mix (pre-collapse): BioXp instruments + kits (the "products" core) + services/collaboration research (higher-margin CRO/grant work) + EtonBio services (divested Aug 2024). BioXp products were the growth story — Q4 2022 BioXp revenue ~$3M, +130% YoY. The higher-margin collaboration/research line was the swing factor — its loss is what cratered both revenue and margin in 2024 (see Lens 5).
- Trend: flat at the top (FY22 ~$27.4M → FY23 ~$27.5M, basically zero growth), then a cliff in 2024 as the company shed the services revenue, divested Eton, and restructured around Gibson SOLA. Geography: not separately disclosed in the PR I can source —
n/a.
- Read: the segment story IS the failure story. A synbio-tools company that stops growing at ~$28M while burning >$40M/yr is structurally dead absent a step-change product — and the step-change (Gibson SOLA) arrived after the balance sheet was already gone.
Phase B — Measure performance
Lens 5 · Earnings Result (the terminal prints)
The last meaningful public prints, all `` (IR releases via StockTitan/Fintel):
- FY2023: total revenue ~$27.5M (vs ~$27.4M FY22 — +0.4%, dead flat).
- Q1 2024: revenue $3.4M; gross margin 42% (down from 56% Q1'23); opex $10.0M (−31% YoY as restructuring bit).
- Q2 2024 (the death-knell quarter): revenue $1.6M vs $7.0M Q2'23 — a −77% collapse; gross margin −52% (vs +71% Q2'23) on restructuring/inventory charges; net loss $13.2M ($7.62/sh post-split) vs $8.4M Q2'23.
- Balance sheet at 30 Jun 2024: $10.3M cash, $5.3M notes payable. Against an opex run-rate of ~$10M/quarter even after cuts, that is roughly one quarter of runway — which is exactly why the delist + private bridge followed within months.
- Market reaction: terminal — the stock was already a sub-$1 penny after the 1-for-18 reverse split (May 9 2024) failed to hold the bid; it delisted to OTC at ~$0.001 by Sept 2024.
Unusual-vs-own-history flag: a swing from +71% to −52% gross margin in one year is not a normal cyclical wobble — it is the signature of revenue evaporating beneath a fixed cost base plus inventory write-downs as the business model was abandoned mid-stream.
Lens 6 · Earnings Calls (sentiment trend)
No transcripts on the shelf ; sentiment reconstructed from the public arc . The tonal trajectory is a textbook bull-to-survival decay:
- 2021 (IPO/Codex DNA Q2'21 call): euphoric — "desktop DNA factory," COVID-vaccine tailwind, TAM-expansion narrative.
- 2022 ("Big Year"/"Whirlwind Year"): still growth-framed (200 instruments, 105 pharma logos), rebrand to Telesis Bio, "platform" language.
- Apr 2024: the pivot is announced as "strategic focus on game-changing Gibson SOLA" — but in the same breath the founder-CEO steps down and the company "concentrates" (i.e. shrinks). "Focus/streamline/runway/supply-chain in-sourcing" replaces "growth."
- 2025–26: the only outward messaging is financing ("secures up to $21M") and partnership (Regeneron license) — classic going-private survival comms, not operating-performance updates. What they stopped saying: revenue growth, installed-base expansion, guidance. What they started saying: "AI drug discovery data ownership," "nucleic-acid supply chain control" — repositioning the same tech for the LLM-era narrative.
Lens 7 · Comps (cap table & peer table — +private overlay)
Public common stock is un-priceable (OTC ~$0.001, no float, no coverage) so a P/E-style table is meaningless — n/a — not a tradeable equity. Two useful frames instead:
(a) Peer landscape — enzymatic / synthetic DNA tools:
| Company | Status | Positioning | Mkt cap / valuation | EV/Sales | Note |
|---|
| Twist Bioscience (TWST) | Public | Scaled silicon DNA synthesis + NGS + biopharma | mid-cap, ~$1–3B range | n/a | The scale winner; reference comp |
| DNA Script | Private (FR/US) | SYNTAX benchtop TdT enzymatic printer | VC-backed (>$200M raised) | n/a — private | The most direct BioXp competitor |
| Ansa Biotechnologies | Private | Long clonal enzymatic DNA; IDT-partnered | VC-backed | n/a — private | Read-length leader (600→5,000 bp) |
| Molecular Assemblies | Shuttered 2024 | Enzymatic DNA; IP → Maravai LifeSciences | — | — | Direct peer that already died |
| Telesis Bio (TBIO) | Delisted/private | BioXp + Gibson SOLA EDS | ~$0 equity; $17M pref bridge | n/a | This dossier |
(b) Cap table / financing quality (the +private tell). The Mar-2025 round is a $21M convertible preferred led by Novalis LifeSciences (Marijn Dekkers' fund) + Northpond Ventures — both existing insiders, not fresh crossover capital. Structure: ~$17M tranche 1 = $8M new cash + $9M debt-to-equity conversion, plus a $4M tranche 2 by Mar 6 2026. Read it straight: only $8M of genuinely new money, the rest is insiders converting debt to avoid a default — the cap-table equivalent of a tourniquet. No tier-1 crossover (no Fidelity/T. Rowe/Coatue) = the opposite of IPO-proximity. Common equity is structurally subordinated to a fresh preferred stack — i.e. wiped to ~zero in any realistic outcome.
Lens 8 · Stock-Price Catalysts (the >5% moves, in order of the wreck)
All ``:
- Jun 18 2021 — IPO at $16 (DNAY), raised ~$122.7M gross, ~$448M fully-diluted cap; brief pop to a split-adjusted all-time-high close ~$396 (Jun 30 2021). (The ~$396 is post-reverse-split-adjusted; the unadjusted IPO-era high was ~$22.)
- 2022 — synbio bubble deflates — rate shock + post-COVID biotech derating; flat revenue can't support the multiple; steady bleed.
- Nov 2022 — rebrand to Telesis Bio/TBIO — neutral-to-negative; doesn't change fundamentals.
- May 6–9 2024 — 1-for-18 reverse split to defend the $1 bid — a distress signal, not a catalyst; bid fails to hold.
- Apr 16 2024 — founder-CEO Todd Nelson out, Eric Esser in; Gibson-SOLA pivot — stock slips.
- Aug 2024 — EtonBio divested; board exodus (Nelson + 4 directors resign) — governance capitulation.
- Sep 10–30 2024 — voluntary delist/deregister → OTC ~$0.001. Terminal.
- Mar 2025 — $21M insider bridge — keeps the company alive; does nothing for the equity.
Pattern the tape reveals: the market only ever rewarded the 2021 bubble narrative; once growth stalled at ~$28M, every subsequent "catalyst" was a defensive corporate action (split, divest, delist, rescue-finance). For a sub-scale tools company, the real driver was always revenue growth + cash runway — and both broke.
Phase C — Judge people & books
Lens 9 · Management
- Track record: Dan Gibson (co-founder/CTO) — scientifically elite: Gibson Assembly is his, synthetic-genome work at Venter's institute is his. As a commercial engine, the record is a near-total capital loss for IPO shareholders. Todd Nelson (founder-CEO through Apr 2024) took the company public and to ~$28M revenue but never to scale or cash generation, then stepped down "to seek new entrepreneurial opportunities" as the wheels came off. Eric Esser (President/COO → CEO Apr 2024) is the restructuring/wind-down operator — his mandate was triage (cut opex, divest Eton, pivot to SOLA, raise the bridge), and on those narrow terms he executed; signing Regeneron to a SOLA license is a real scalp in a dead-broke context.
- Tenure & skin in the game: founder ownership was heavily diluted and then subordinated by the preferred bridge; insider economics now sit with Novalis/Northpond's preferred, not common.
Insider-transactions.csv: n/a.
- Capital-allocation history (the indictment): raised $122.7M at IPO and destroyed essentially all common-equity value — ROE/ROIC deeply negative throughout; spread spend across BioXp, services, EtonBio, and a from-scratch enzymatic platform simultaneously, then had to fire-sale and refocus only after the cash was gone. Classic sub-scale-tools over-reach: too many bets, none to escape velocity.
- Red flags: founder + 4-director board exodus within months of the pivot (Aug 2024) is a governance red flag; a reverse split immediately preceding voluntary delisting is the textbook distress sequence; the debt-to-preferred conversion is an insider-favorable recap that subordinates common.
- Archetype: scientist-founder company that needed a commercial operator five years earlier. The science was the asset; the go-to-market and capital discipline were the failure.
Lens 10 · Forensic Red Flags
Income statement / balance sheet / cash flow (all ``, mostly the company's own pre-deregistration disclosure):
- Revenue quality / recognition: the swing to −52% gross margin in Q2'24 on a −77% revenue drop screams fixed-cost deleverage + inventory write-downs + restructuring charges — i.e. the model unwinding. Watch that the FY22→FY23 "flat $27.4M→$27.5M" wasn't propped by lower-quality services/collaboration revenue that then vanished (it was — its loss drove the 2024 cliff).
- Going concern: with $10.3M cash / ~$10M quarterly opex at Jun-2024, substantial-doubt going-concern territory was effectively reached; the delist + bridge confirm it. Post-deregistration, financials are unaudited / not publicly filed — a structural disclosure red flag in itself (you can no longer see the books).
- Receivables/inventory vs revenue: inventory clearly outran a collapsing top line (hence the margin charges); specifics
n/a — post-delist financials not filed.
- SBC / dilution: chronic — IPO shares + subsequent raises + the 1-for-18 reverse split + the convertible preferred = relentless common-holder dilution then subordination.
- Goodwill/intangibles: EtonBio divestiture implies prior-acquisition carrying values were impaired/realised below cost (a fire sale for cash).
Regulatory findings (required sub-section).
- SEC enforcement (EDGAR LR/AAER): `` reports 0 findings — and notes the file could not search EDGAR because
_meta.json carries cik=null (the script saw no CIK). In reality TBIO held CIK 0001850079; I did not re-run EDGAR (mandate: EDGAR 403s; on-disk is authoritative). No SEC enforcement action against Telesis Bio surfaced in any web search.
- Non-SEC (FTC/DOJ/FDA/CFPB): web search
"Telesis Bio" (FTC OR DOJ OR FDA OR... ) enforcement → no material hits.
- 10-K Item 3 (Legal Proceedings): could not retrieve the last 10-K (FY2023, filed Mar 2024) directly — EDGAR archive 403s ``; no material litigation surfaced via web.
- Conclusion: No material regulatory or legal enforcement findings — verified via the on-disk regulatory file (SEC LR/AAER = 0) + web search (non-SEC) as of 2026-06-30. The risk here is not fraud — it is honest, total business failure plus the opacity of a now-deregistered private whose books are no longer public.
Phase D — Project & stress-test
Lens 11 · IPO-readiness & path-to-tradeable (+private overlay — replaces forward EPS)
There is no EPS to forecast and no forecast logged (forecast.ts skipped, per --watchlist rules) — a delisted shell with negative gross margin has no projectable earnings line. The right question is the +private one: is there any path back to a tradeable security, and what is the common stock worth today?
- Path-to-tradeable: remote. A company that voluntarily deregistered would have to (re-)build audited financials, demonstrate Gibson-SOLA commercial traction at scale, and either re-IPO or be acquired — all from a ~$8M-new-cash base against scaled, better-funded competitors (Twist, DNA Script, Ansa/IDT).
research/private-watch.json: not listed — this is not a tracked IPO-readiness candidate, and shouldn't be added as one.
- Realistic outcomes (probability-weighted, ``): (1) Slow fade / asset sale — Gibson-SOLA IP sold to a strategic (à la Molecular Assemblies → Maravai), common = $0 — most likely. (2) Private survival as a niche SOLA/BioXp supplier funded round-to-round by Novalis/Northpond — possible, common still ~$0 (preferred eats any value). (3) Re-rating/re-IPO on SOLA + AI-drug-discovery traction — low-probability tail; would need a genuine commercial inflection the financials don't yet show.
- Common-equity value today:
~$0 / option-value only. The only way to "play" this is the private preferred (Novalis/Northpond terms), which is not accessible and is itself a venture call option on an unproven pivot.
Lens 12 · Bull vs Bear
Bull case (for the surviving private entity, not the dead stock): Gibson SOLA is a legitimately differentiated enzymatic platform — overnight DNA and mRNA on standard liquid handlers (no proprietary printer), pitched at exactly the 2025-26 zeitgeist: pharma wanting to in-source nucleic-acid supply and own the data to train AI drug-discovery models. The Regeneron license proves a tier-1 customer will pay. The EDS market is real and fast (~$371M 2025 → ~26.7% CAGR). Heritage (Gibson Assembly / Venter lineage) is unmatched. In a kinder capital market this is a fundable Series-C synbio-tools story.
Bear case (permanent-impairment risks): (1) The balance sheet already lost — common is wiped; only $8M new cash stands between the company and another raise/sale. (2) Sub-scale against funded peers — Twist's economics, DNA Script's commercial momentum, Ansa+IDT's read-length and manufacturing all overshadow a near-bankrupt rebuilder. (3) The pivot is late — Gibson SOLA's commercial ramp is starting after the cash ran out, the worst possible sequencing. Pre-mortem (it's now end-2027 and it's over): the $4M tranche-2 was the last money, SOLA's enterprise sales cycle proved too slow against incumbents, and the IP was sold to a strategic for cents while the corporate shell wound down — the Molecular-Assemblies ending. Multiple too high? There is no multiple; the common is a zero, and even the private preferred is a low-odds venture bet.
Contrarian view (what the market refuses to see — but here the market is right): the technology may well live on — inside Regeneron, or inside whoever buys the SOLA IP. The contrarian read isn't "the stock is cheap" (it's a zero); it's that a genuinely good synthetic-biology platform can be a complete equity wipeout — the science succeeding and the shareholders being destroyed are not contradictory. That is the durable lesson, not a trade.
Lens 13 · Devil's Advocate (short-seller)
There is nothing left to short (no borrow, ~$0.001, deregistered) — so this lens is the autopsy of how the bull thesis was always going to break:
- Where revenue was concentrated: in lumpy instrument sales + fragile higher-margin services/collaboration revenue with no recurring-consumable annuity at scale — so when the services line and grant/collab work rolled off, 77% of a quarter's revenue vanished at once.
- Why the moat was always weaker than bulls thought: "DNA printer" is a substitutable value prop — customers can buy DNA as a service from Twist/IDT/Genscript or run DNA Script's competing benchtop box; no switching cost, no network effect, negative pricing power.
- Most dangerous competitor bulls underestimated: DNA Script (same benchtop-enzymatic promise, more commercial traction) and the Ansa + IDT combination (read-length + manufacturing scale) — plus Twist simply out-spending everyone.
- Worst capital-allocation: running four initiatives at once (BioXp instruments, kits, EtonBio services, and a ground-up enzymatic platform) on IPO cash, then fire-selling Eton and reverse-splitting into a delisting; the debt-to-preferred recap that subordinated common.
- What had to hold for the 2021 price (and didn't): 20%+ revenue CAGR to a $100M+ run-rate with expanding consumable margin — instead it flatlined at ~$28M. −20–30% to growth? Growth went to −77%; the valuation went to zero. That's the whole story.
Lens 14 · Management Questions (ordered by information value — addressed to CEO Eric Esser)
- With ~$8M of genuinely new cash from the 2025 round and a $4M tranche-2 deadline of Mar 2026, how many months of runway do you actually have, and what is the specific commercial milestone that unlocks the next financing or a strategic sale?
- Is the plan to rebuild toward audited financials and a re-listing, to be acquired, or to run privately indefinitely? Be concrete about which.
- Beyond the Regeneron license, how many paying Gibson-SOLA enterprise customers exist today, and what is committed contract value vs. pilot/evaluation?
- What is Gibson SOLA's gross margin at current volumes, and at what unit volume does the consolidated business reach positive gross margin again?
- How do you win against DNA Script (benchtop enzymatic) and Twist on cost-per-base, fidelity, and read-length — name the spec where SOLA is decisively ahead.
- What were the terms of the Novalis/Northpond preferred (liquidation preference, conversion, participation), and what, if anything, is the common stock entitled to in a sale?
- Why should a customer in-source synthesis on SOLA rather than buy DNA/mRNA as a service from incumbents — what's the real TCO and IP-control case, quantified?
- What is the current BioXp installed base and consumable reorder rate, and is that annuity growing or shrinking post-restructuring?
- What did the EtonBio divestiture net in cash, and were any other assets/IP encumbered or sold to fund operations?
- What is the current headcount vs. the 2023 peak, and is R&D still funded enough to keep SOLA competitive on read-length?
- Which patents are core to SOLA, when do they expire, and is the IP unencumbered (not pledged to lenders)?
- What specifically broke in 2024 — was it the loss of collaboration revenue, the consumable attach never scaling, or the cost base? Own the root cause.
- For AI-drug-discovery data ownership as a selling point — do you have a single customer paying for that reason, or is it narrative?
- Under what circumstances would you sell the SOLA IP to a strategic (the Molecular-Assemblies/Maravai path) rather than keep operating?
- What would you tell a 2021 IPO shareholder about where the $122.7M went and why the equity is at zero?